Literature DB >> 15782125

Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.

Daniele Bergamaschi1, Yardena Samuels, Shan Zhong, Xin Lu.   

Abstract

Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15782125     DOI: 10.1038/sj.onc.1208535

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

2.  Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors.

Authors:  K Rohini; J Mathivanan; P D Antony Herold Prabhu; D K Subbakrishna; M L Gope; B A Chandramouli; S Sampath; B Anandh; R Gope
Journal:  Mol Cell Biochem       Date:  2006-12-16       Impact factor: 3.842

3.  Nucleostemin and ASPP2 expression is correlated with pituitary adenoma proliferation.

Authors:  Lin Ma; Zhi-Min Chen; Xue-Yuan Li; Xin-Jun Wang; Ji-Xin Shou; Xu-Dong Fu
Journal:  Oncol Lett       Date:  2013-09-04       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.